US biotech Arbutus Biopharma (Nasdaq: ABUS) has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), ...

Under the deal, Qilu will have exclusive rights to the therapy in Mainland China, Macau, Taiwan, and Hong Kong. Meanwhile, Minghui is qualified for up to 1.345bn yuan ($185m), including an upfront ...

Qilu Pharmaceutical is paying 280 million Chinese yuan ($38 million) for a licensing and collaboration deal with fellow China biopharma Minghui Pharmaceutical. The pact centers on MHB088C, a B7-H3 ...

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan ...

Mabwell’s subsidiary T-mab enters into an agreement with Qilu Pharma for Albipagrastim alfa for injection: Shanghai Monday, June 30, 2025, 15:00 Hrs [IST] Mabwell, an innovative ...

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an agreement with Qilu Pharmaceutical for ...

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with ...

WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it has reacquired full global rights to its lead RNAi ...

Minghui Pharmaceutical has announced an exclusive licensing and partnership agreement with Qilu Pharmaceutical for developing, manufacturing, and commercialising MHB088C in Greater China. Under ...

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with ...

SHANGHAI, May 9, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced an exclusive licensing and collaboration agreement with ...